Read by QxMD icon Read


E A Aalbersberg, B J de Wit-van der Veen, M W J Versleijen, L J Saveur, G D Valk, M E T Tesselaar, M P M Stokkel
INTRODUCTION: Somatostatin receptor imaging with PET is the standard of care for patients with a neuroendocrine tumour (NET). Since therapy and imaging with somatostatin analogues utilize the same receptor, current guidelines recommend withdrawing long-acting somatostatin analogues for 3-4 weeks prior to somatostatin receptor PET imaging. The aim of this study is to prospectively assess the effect of lanreotide use on the uptake of 68 Ga-DOTATATE intra-individually 1 day prior to and 1 day post injection of lanreotide...
August 10, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Ming Yang, Krupa B Doshi, Michael C Roarke, Ba D Nguyen
Tumor induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23 (FGF23) secreted by benign mesenchymal neoplasm. Due to its nonspecific clinical presentation or lack of awareness, the diagnosis of TIO is often significantly delayed resulting in patients' prolonged physical suffering or psychological distress. Successful detection or complete surgical resection of the causative tumor typically leads to rapid resolution of symptoms or reversal of biochemical imbalance...
June 27, 2018: Current Problems in Diagnostic Radiology
Amanda Abbott, Christopher G Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H Kulke, Jennifer A Chan, Heather A Jacene, Annick D Van den Abbeele
[Lutetium-177-DOTA(0),Tyr(3)]octreotate (177 Lu-DOTATATE) is a radiolabeled somatostatin analog that has been approved by the U.S. Food and Drug Administration for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults. Radionuclide therapies have been administered for many years within nuclear medicine departments in North America. However, in comparison to other radiotherapies, 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) involves more planning, coordination, concomitant medication administration (anti-emetic medications and amino acids) and direct patient care...
August 3, 2018: Journal of Nuclear Medicine Technology
Amanda Abbott, Heather A Jacene
No abstract text is available yet for this article.
August 3, 2018: Journal of Nuclear Medicine Technology
Frederik Giesel, Clemens Kratochwil, Thomas Lindner, Manfred Marschalek, Anastasia Loktev, Wencke Lehnert, Jürgen Debus, Dirk Jäger, Paul Flechsig, Annette Altmann, Walter Mier, Uwe Haberkorn
Purpose: Fibroblast activation protein (FAP) is overexpressed in cancer associated fibroblasts of several tumor entities. Recent development of quinoline based positron-emission-tomography (PET)-tracers that act as FAP-Inhibitors (FAPI) demonstrated promising results preclinically and already also in few clinical cases. Consecutively this novel tracer is now applied in our hospital to amend the diagnostics of cancer patients facing limitations of standard exams. Here we analyze the tissue biodistribution and preliminary dosimetry of two members of this new class of PET-radiopharmaceuticals...
August 2, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Zhaoting Cheng, Shuang Song, Yunfeng Han, Sijuan Zou, Xiaohua Zhu
Ga-DOTATATE PET/CT was performed in a 60-year-old man to detect culprit tumor responsible for tumor-induced osteomalacia (TIO). The images revealed multiple foci of abnormal activity in soft tissue lesion, which were not typical of tumor causing TIO in Ga-DOTATATE PET/CT. Considering other neoplastic processes, FDG PET/CT were subsequently performed, which showed all same lesions, although the lesions with highest activity were different between the scans. Pathological examination demonstrated that the patient experienced TIO caused by 1 lesion, but other lesions were due to IgG4-related lymphadenopathy...
July 27, 2018: Clinical Nuclear Medicine
Wolfgang Roll, Burkhard Riemann, Michael Schäfers, Lars Stegger, Alexis Vrachimis
INTRODUCTION: Patients with radioiodine-refractory differentiated thyroid cancer (RrDTC) have a rather poor prognosis and are in need of novel treatments. As RrDTCs can in some cases express somatostatin receptors (SSRT), targeting of these receptors by Ga/Lu-DOTATATE could evolve as a novel theranostic option. METHODS: Five RrDTC patients with limited further therapeutic options and documented expression of SSRT using Ga-DOTATATE-PET/CT received 2 to 4 cycles of PRRT with Lu-DOTATATE...
July 27, 2018: Clinical Nuclear Medicine
Roberto A Escala Cornejo, Paloma García-Talavera, Miguel Navarro Martin, Berta Pérez López, María García Muñoz, Ma Pilar Tamayo Alonso, Juan J Cruz Hernández
Large cell neuroendocrine carcinoma of the lung (LCNEC) is a high-grade, poorly differentiated tumor that typically does not express somatostatin receptors. Thus, it does not benefit from treatment with somatostatin analogs and peptide receptor radionuclide therapy (PRRT). The current study objective was to demonstrate that treatment with PRRT may be a valid option in neuroendocrine carcinomas with high expression of somatostatin receptors. This is a case report of a 58-year-old man who was diagnosed with LCNEC and received chemotherapy treatment with little benefit...
July 26, 2018: Annals of Nuclear Medicine
Caroline Martini, Sabine Buxbaum, Margarida Rodrigues, Bernhard Nilica, Lorenza Scarpa, Bernhard Holzner, Irene Virgolini, Eva-Maria Gamper
We evaluated health-related quality of life (HRQoL) in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEPNET) over the course of first peptide receptor radionuclide therapy (PRRT) to first restaging, and compared scores with general population (GP) norms. Methods: We used data from routine HRQoL monitoring with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30. Patients received 4-6 cycles of 177 Lu-DOTATATE or 90 Y-DOTATOC. To be eligible for analysis, patients had to have at least one HRQoL assessment before PRRT and one after treatment completion...
July 24, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Krzysztof Kilian, Łukasz Cheda, Mateusz Sitarz, Katarzyna Szkliniarz, Jarosław Choiński, Anna Stolarz
The rapid increase in applications of scandium isotopes in nuclear medicine requires new efficient production routes for these radioisotopes. Recently, irradiations of calcium in cyclotrons by α, deuteron, and proton beams have been used. Therefore, effective post-irradiation separation and preconcentration of the radioactive scandium from the calcium matrix are important to obtain the pure final product in a relatively small volume. Nobias resin was used as a sorbent for effective separation of 44 Sc from calcium targets...
July 20, 2018: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
Rathan M Subramaniam
No abstract text is available yet for this article.
August 2018: AJR. American Journal of Roentgenology
David P Nadebaum, Sze Ting Lee, Mehrdad Nikfarjam, Andrew M Scott
68 Ga-DOTATATE positron emission tomography (PET) is a molecular imaging technology which has shown superiority over 111 In-octreotide scanning for the detection and staging of neuroendocrine tumors. We report three patients with pancreatic masses that were ultimately diagnosed as clear cell renal cell carcinoma (ccRCC) metastases on histopathology. During their initial diagnostic assessment, the three patients underwent both 18 F-fluorodeoxyglucose (18 F-FDG) and 68 Ga-DOTATATE PET. While all three patients' lesions showed variable 18 F-FDG avidity, uptake on 68 Ga-DOTATATE PET was comparatively intense...
July 2018: World Journal of Nuclear Medicine
Sangwon Han, Chong Hyun Suh, Sungmin Woo, Yeon Joo Kim, Jong Jin Lee
We performed a systematic review and meta-analysis of the performance of 68 Ga-DOTA-conjugated somatostatin receptor targeting peptides (68 Ga-DOTA-SST) PET in the detection of pheochromocytomas and paragangliomas (PPGLs). Methods: PubMed and Embase were searched until 08 May 2018. We included studies that reported the detection rate of 68 Ga-DOTA-SST PET in patients with PPGLs. Detection rates were pooled using a random-effects model. Subgroup analyses and meta-regression were performed to explore the cause of heterogeneity...
July 20, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Parul Thakral, Ishita Sen, Vineet Pant, Santosh Kumar Gupta, Sugandha Dureja, Jyotsna Kumari, Sunil Kumar, Pallavi Un, Vindhya Malasani
OBJECTIVE: Two radiosensitizing chemotherapeutic drugs, capecitabine (CAP) and temozolomide (TEM), are administered concurrently to enhance the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT). This study aims to assess the biodistribution and normal-organ and tumor radiation dosimetry for Lu-177 DOTATATE administered concurrently with CAP/TEM. METHODS: 20 patients with non-resectable histologically confirmed gastroenteropancreatic neuroendocrine tumors with normal kidney function, a normal haematological profile and somatostatin receptor expression of the tumor lesions, as scintigraphically assessed by a Ga-68 DOTANOC scan, were included in two groups-case group (n = 10) and control group (n = 10)...
July 27, 2018: British Journal of Radiology
Mathias Tesson, Richa Vasan, Andreas Hock, Colin Nixon, Colin Rae, Mark Gaze, Robert Mairs
Targeted radiotherapy of metastatic neuroblastoma using the somatostatin receptor (SSTR)-targeted octreotide analogue DOTATATE radiolabelled with lutetium-177 (177 Lu-DOTATATE) is a promising strategy. This study evaluates whether its effectiveness may be enhanced by combination with radiosensitising drugs. The growth rate of multicellular tumour spheroids, derived from the neuroblastoma cell lines SK-N-BE(2c), CHLA-15 and CHLA-20, was evaluated following treatment with 177 Lu-DOTATATE, nutlin-3 and topotecan alone or in combination...
June 26, 2018: Oncotarget
Jie Ding, Ling Wang, Shu Zhang, Fang Li, Li Huo
Phosphaturic mesenchymal tumors are benign tumors causing majority of tumor-induced osteomalacia. These tumors are most commonly located in the lower extremities followed by craniofacial regions. However, intracranial lesion is very rare. Here we describe Ga-DOTATATE PET/CT findings of a recurrent intracranial phosphaturic mesenchymal tumor in a 68 year old woman.
September 2018: Clinical Nuclear Medicine
Rudolf A Werner, Harun Ilhan, Sebastian Lehner, László Papp, Norbert Zsótér, Imke Schatka, Dirk O Muegge, Mehrbod S Javadi, Takahiro Higuchi, Andreas K Buck, Peter Bartenstein, Frank Bengel, Markus Essler, Constantin Lapa, Ralph A Bundschuh
PURPOSE: Early identification of aggressive disease could improve decision support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-positron emission tomography (PET) before PRRT was analyzed. PROCEDURES: Thirty-one patients with G1/G2 pNET were enrolled (G2, n = 23/31). Prior to PRRT with [177 Lu]DOTATATE (mean, 3...
July 16, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
Kathy P Willowson, HyunJu Ryu, Price Jackson, Anita Singh, Enid Eslick, Dale L Bailey
Objectives: To investigate and compare quantitative accuracy of kidney absorbed dose measures made from both 2D and 3D imaging in patients receiving 177 Lu-DOTATATE (Lutate) for treatment of neuroendocrine tumours (NETs). Methods: Patients receiving Lutate therapy underwent both whole body planar imaging and SPECT/CT imaging over the kidneys at time points 0.5, 4, 24, and 96-120 hours after injection. Planar data were corrected for attenuation using transmission data, and were converted to units of absolute activity via two methods, using either a calibration standard in the field of view or relative to pre-voiding image total counts...
2018: Asia Oceania Journal of Nuclear Medicine & Biology
Stephen M Broski, Andrew L Folpe, Doris E Wenger
OBJECTIVE: To examine the CT and MR imaging features of phosphaturic mesenchymal tumors (PMTs). MATERIALS AND METHODS: With IRB approval, our institutional radiology/pathology database was reviewed for pathologically-proven PMTs. CT and MRI examinations were reviewed in consensus noting several imaging features, and if available, comparative molecular imaging tests were analyzed. RESULTS: We identified 39 patients (21 male, 18 females) with 40 PMTs [mean age, 52...
July 9, 2018: Skeletal Radiology
Yasemin Sanli, Ishan Garg, Asha Kandathil, Tuba Kendi, Maria J Baladron Zanetti, Serkan Kuyumcu, Rathan M Subramaniam
OBJECTIVE: The purpose of this article is to provide a review of the use of 68 Ga tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68 Ga-DOTATATE PET/CT as an appropriate test in the management of NETs...
August 2018: AJR. American Journal of Roentgenology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"